Vincere Biosciences Awarded $2.7 Million NIH Grant to Advance USP30 Inhibitor for Acute Kidney Injury

Vincere Biosciences received an SBIR Phase II award from the National Institute of Diabetes and Digestive and Kidney Diseases to fund IND-enabling development of its USP30 small-molecule inhibitor for acute kidney injury. The program targets mitochondrial dysfunction and impaired cellular quality control, advancing the company’s preclinical therapeutic candidate toward an IND filing. The non-dilutive funding is a positive development for Vincere but is unlikely to have broad market impact.